Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/0003319714536602 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Survival after aluminum phosphide poisoning with cardiotoxicity: a case report.
J Med Case Rep
December 2024
Department of Internal Medicine, Woldia Comprehensive Specialized Hospital, Woldia, Ethiopia.
Introduction: Aluminum phosphide is a cheap and commonly used rodenticide that is also an effective solid fumigant and frequently used for grain preservation. The pill contains around 44% inert elements (ammonium carbonate) to avoid disintegration of the tablet, while the rest (about 56%) is aluminum phosphide. Because it is freely available on the market, it is one of the commonly used agents for self-poisoning in different parts of the developing world.
View Article and Find Full Text PDFCardiovascular diseases in patients with cancer: A comprehensive review of epidemiological trends, cardiac complications, and prognostic implications.
Chin Med J (Engl)
December 2024
Keele Cardiovascular Research Group, Institute for Prognosis Research, University of Keele, Keele, ST5 5BG, United Kingdom.
This article provides an overview of the current evidence on the epidemiology, overlapping risk factors, and pathophysiology of cardiovascular disease (CVD) in patients with cancer. It explores the cardiotoxic effects of anticancer therapy and their impact on prognosis. Although cancer survival rates have improved over the last two decades, the risk of CVD has risen over time in patients with cancer.
View Article and Find Full Text PDFFrequency of ischemic cardiac events in patients receiving long-term multikinase inhibitor: A report of three cases.
Asia Pac J Oncol Nurs
December 2025
Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Objective: To investigate the incidence and characteristics of ischemic cardiac events, specifically major adverse cardiac events (MACE), in patients undergoing long-term treatment with multikinase inhibitors (MKIs) such as lenvatinib and sorafenib.
Methods: A single-center retrospective analysis was conducted on 41 patients treated with lenvatinib or sorafenib for more than one year at our institution from 2015 to 2022. Patient records were reviewed to collect data on demographics, cancer type, cardiovascular risk factors, MKI treatment duration, and MACE incidence.
Dose-volume predictors of cardiac adverse events after high-dose thoracic radiation therapy for lung cancer: a systematic review and meta-analysis.
BMC Cancer
December 2024
Department of Biomedical Sciences, Namur Research Institute for Life Sciences, (NARILIS), Faculty of Medicine, University of Namur, Namur, Belgium.
Background: Lung cancer is a leading cause of cancer mortality and may require high-dose thoracic radiation therapy (RT). However, RT significantly increases the risk of radiation-induced cardiac events, such as pericarditis, cardiomyopathy, and ischemic heart diseases. Despite evidence from clinical trials showing that higher RT doses are associated with poorer survival outcomes due to these cardiac effects, data on dose-volume predictors of such events in lung cancer remain sparse.
View Article and Find Full Text PDFDifferential cardiac impacts of hematological malignancies and solid tumors: a histopathological and biomarker study.
Cardiooncology
December 2024
Department of Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Background: Cancer patients are known to be associated with increased risk of cardiovascular disease. However, no studies have examined the differential impact of hematologic malignancies (HMs) and solid tumors (STs) on cardiac morphology at the tissue level.
Objective: We aimed to examine histopathological features alongside cardiovascular biomarkers in patients with HMs and STs who underwent post-mortem evaluation.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!